• GC Biopharma signed a KRW 59.16 billion influenza vaccine supply contract with VaxThera Zona Franca on Oct. 30, 2026.
• The USD 44.31 million deal represents 2.97% of 2025 consolidated revenue.
• Supply to Colombia runs from Oct. 30, 2026, through Oct. 30, 2036.
• The contract includes technical support for local production; its value combines minimum purchase commitments with license fees.
• Exports can begin once local regulatory approval is secured, with VaxThera responsible for obtaining authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GC Biopharma Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800297), on November 02, 2026, and is solely responsible for the information contained therein.